Anita H. Clayton, MD

When Do Physical Symptoms After Antidepressant Cessation Reflect Pharmacodynamic versus Non-pharmacodynamic Clinical Phenomena?

August 6, 2026

Focuses on descriptive symptom phenomenology and strategies to minimize discomfort during antidepressant cessation, with possible explanations for unusual, delayed, or protracted symptoms in patients for whom non-pharmacodynamic features may...

Joseph F. Goldberg, M. Lynn Crismon, David W. Goodman, et al

Original Research

Gepirone-ER and Sexual Function in Patients with MDD

October 21, 2024

Rates of sexual side effects and treatment-emergent sexual dysfunction with gepirone-ER were similar to placebo and lower than sexual side effects reported for SSRIs.

Tierney K. Lorenz, Mary F. Johnson, Anita H. Clayton

Supplement Article

The GABA Pathway and New Clinical Trial Data in MDD and PPD

March 16, 2023

Studies evaluating neuroactive steroid GABA-A receptor positive allosteric modulators demonstrate promising results for the treatment of MDD and PPD.

Kristina M. Deligiannidis, Anita H. Clayton

Original Research

Effect of Zuranolone vs Placebo in MDD

February 20, 2023

This phase 3 RCT found significant improvement in depressive symptoms with zuranolone beginning at day 3 of treatment.

Anita H. Clayton, Robert Lasser, Indrani Nandy, et al

Original Research

Lurasidone and Sexual Function

August 7, 2018

As you probably know, sexual dysfunction is a common side effect of antidepressants and antipsychotics. This secondary analysis of an RCT examines whether the atypical antipsychotic lurasidone was linked...

Andrei Pikalov, Anita H. Clayton, Joyce Tsai, et al

Original Research

Desvenlafaxine 50 and 100 mg/d Versus Placebo for the Treatment of Major Depressive Disorder: A Phase 4, Randomized Controlled Trial

October 28, 2014

Michael E. Thase, Anita H. Clayton, Kristen Focht, et al

Article

Prevalence of Substance Misuse in New Patients in an Outpatient Psychiatry Clinic Using a Prescription Monitoring Program

January 2, 2014

The purpose of this study was to investigate the value of a prescription monitoring program in identifying prescription drug misuse among patients presenting to a resident physicians' outpatient psychiatry...

Anita H. Clayton, Elle M. Sowa, Jonathan C. Fellers, et al

Article

Efficacy and Safety of Desvenlafaxine 50 mg/d in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder

October 15, 2013

Susan G. Kornstein, Philip T. Ninan, Boadie W. Dunlop, et al

Educational Activity

Understanding Antidepressant Mechanism of Action and Its Effect on Efficacy and Safety

March 15, 2012

Anita H. Clayton

Article

Depression or Menopause? Presentation and Management of Major Depressive Disorder in Perimenopausal and Postmenopausal Women

February 18, 2010

In this review article, examine the risk of depression onset in perimenopausal and postmenopausal women and find out how to screen for and manage depression in your perimenopausal and...

Philip T. Ninan, Anita H. Clayton

Article

Distressing Sexual Problems in United States Women Revisited: Prevalence After Accounting for Depression

December 15, 2009

Anita H. Clayton, Catherine B. Johannes, Dawn M. Odom, et al

Letter to the Editor

Onset of Obstructive Sleep Apnea After Initiation of Psychotropic Agents

December 14, 2007

Anita H. Clayton, Atma R. Yarlagadda, Anita B. Brown

When Do Physical Symptoms After Antidepressant Cessation Reflect Pharmacodynamic versus Non-pharmacodynamic Clinical Phenomena?

Gepirone-ER and Sexual Function in Patients with MDD

The GABA Pathway and New Clinical Trial Data in MDD and PPD

Effect of Zuranolone vs Placebo in MDD

Lurasidone and Sexual Function

Desvenlafaxine 50 and 100 mg/d Versus Placebo for the Treatment of Major Depressive Disorder: A Phase 4, Randomized Controlled Trial

Prevalence of Substance Misuse in New Patients in an Outpatient Psychiatry Clinic Using a Prescription Monitoring Program

Efficacy and Safety of Desvenlafaxine 50 mg/d in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder

Understanding Antidepressant Mechanism of Action and Its Effect on Efficacy and Safety

Depression or Menopause? Presentation and Management of Major Depressive Disorder in Perimenopausal and Postmenopausal Women

Distressing Sexual Problems in United States Women Revisited: Prevalence After Accounting for Depression

Onset of Obstructive Sleep Apnea After Initiation of Psychotropic Agents

ELSEWHERE:

FOLLOW US:

Anita H. Clayton, MD

When Do Physical Symptoms After Antidepressant Cessation Reflect Pharmacodynamic versus Non-pharmacodynamic Clinical Phenomena?

Gepirone-ER and Sexual Function in Patients with MDD

The GABA Pathway and New Clinical Trial Data in MDD and PPD

Effect of Zuranolone vs Placebo in MDD

Lurasidone and Sexual Function

Desvenlafaxine 50 and 100 mg/d Versus Placebo for the Treatment of Major Depressive Disorder: A Phase 4, Randomized Controlled Trial

Prevalence of Substance Misuse in New Patients in an Outpatient Psychiatry Clinic Using a Prescription Monitoring Program

Efficacy and Safety of Desvenlafaxine 50 mg/d in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder

Understanding Antidepressant Mechanism of Action and Its Effect on Efficacy and Safety

Depression or Menopause? Presentation and Management of Major Depressive Disorder in Perimenopausal and Postmenopausal Women

Distressing Sexual Problems in United States Women Revisited: Prevalence After Accounting for Depression

Onset of Obstructive Sleep Apnea After Initiation of Psychotropic Agents

Learn More About Psychedelics in Psychiatry

Subscribe to readmore articles

Subscribe to read
more articles